|
HCV
Genotype 1 - 6
HCV Subtypes Variants
Genotype
1 and 4 Articles
Genotype
2 and 3 Articles
Genotype
5 and 6 Articles
 Genotypes
1 and 4
 Three-quarters
of People with Hepatitis C in the U.S. Have Hard-to-treat
Genotype 1
10/01/2010
Many
Genotype 1 Hepatitis
C Patients Can Be Cured with 24 Weeks of Telaprevir
plus Pegylated Interferon/ribavirin
4/28/2010
HCV
Polymerase Inhibitor VX-222 Demonstrates Good Safety
and Antiviral Activity in Treatment-naive Genotype
1 Hepatitis C Patients
4/23/2010
Experimental
HCV Protease Inhibitor BI 201335 Shows Robust Antiviral
Activity in Genotype 1 Non-responders
4/23/2010
Predictors of Rapid
and Early Virological Response to
Pegylated Interferon plus Ribavirin in Genotype
1 Hepatitis C Patients
4-9-2010
Older Hepatitis C
Patients Have More Side Effects from Interferon-based
Therapy, but Many Can Achieve Sustained Response
3/30/2010
Shorter
Treatment May Be Adequate for Genotype
1 Hepatitis C If Started during Acute Infection
2/23/2010
Can
Some Genotype 1
Chronic Hepatitis C Patients Benefit from Shorter Interferon-based
Treatment?
2/16/2010
Hepatitis C Treatment
Appears to Be Declining; People with Hard-to Treat Genotypes
Are Half as Likely to Receive Therapy
12/01/09
Genotype
1 Chronic Hepatitis C Patients with Low Viral
Load Can Achieve Sustained Response with 24 Weeks of
Pegylated Interferon plus Ribavirin
11/17/09
InterMune
and Roche Begins Trial of Ritonavir-boosted ITMN-191
(RG7227) for Genotype 1
Chronic Hepatitis C Patients
10/06/09
Detectable HCV RNA at Week
8 Is Best Predictor of Relapse in Genotype
1 Hepatitis C Patients Treated with Pegylated
Interferon plus Ribavirin
6/23/09
Adding
Telaprevir Improves Sustained Response to Pegylated
Interferon plus Ribavirin in Genotype
1 Chronic Hepatitis C Patients (PROVE3)
5/05/09
Pegylated
Interferon alfa-2a (Pegasys) Relapse Rates in Genotype
1 Chronic Hepatitis C Patients Depend on
Weight-based Ribavirin Dosage
4/07/09
Widespread
Hepatitis C Treatment Has Led to a Shift in HCV
Genotypes in Spain
3/27/2009
Extended
Pegylated Interferon plus Ribavirin Therapy Improves
Sustained Response Rate in Slow Responder Genotype
1b Hepatitis C Patients
2/03/2009
Genotype
1 HCV Patients with Early but Not Rapid Response
May Benefit from 72 Weeks of Pegylated Interferon plus
Ribavirin
11/18/2008
Response
to Pegylated Interferon plus Ribavirin in Asian Patients
with Genotype 1
Chronic Hepatitis C
10/21/2008
24
Weeks of Pegylated Interferon plus Ribavirin May Be
Sufficient for Selected Genotype
1/4 Chronic Hepatitis C Patients with Rapid
Response
10/14/08
74
Percent of Genotype 1
HCV Patients in Experimental HCV PI Boceprevir Phase
II Study Achieve Sustained Virologic Response (SVR)
at 48 Weeks
8/05/2008
Adequate
Ribavirin Exposure after the First Dose Predicts Sustained
Virological Response to Hepatitis C Treatment in Genotype
1 Patients
7/08/08
HCV Genotype 1 Patients with High Viral
Load Do Better with 48 vs 24 Weeks of Treatment, despite
Rapid Virological Response
7/04/08
Genotypes 2 and 3
Can
Chronic Hepatitis C Patients with Genotypes
2 or 3 Benefit from Shorter Interferon Treatment?
10/26/2010
Experimental
HCV Polymerase Inhibitor RG7128 Is Effective with Standard
Therapy in Genotype 2/3
Patients
4/23/2010
Older Hepatitis C
Patients Have More Side Effects from Interferon-based
Therapy, but Many Can Achieve Sustained Response
3/30/2010
Hepatitis C Treatment
Appears to Be Declining; People with Hard-to Treat Genotypes
Are Half as Likely to Receive Therapy
12/01/09
HCV
Genotype 3 May
Be Associated with More Rapid Liver Fibrosis Progression
in People with Chronic Hepatitis C
10-27-2009
Older
Genotype 3 Chronic
Hepatitis C Patients Do Not Respond as Well to Interferon-based
Therapy
6-16-2009
Reduced
Dose and Duration of PegIntron plus Ribavirin Is Not
as Effective as Standard Therapy for Genotype
2 and 3 Hepatitis C Patients
5-29-2009
Widespread
Hepatitis C Treatment Has Led to a Shift in HCV
Genotypes in Spain
3/27/2009
Combination
Therapy with Investigational HCV Polymerase Inhibitor
R7128 Produces Rapid Response in Patients with Genotype
2/3 HCV
9/12/2008
Body
Weight Affects Relapse Rates in Latinos with Genotype
2/3 Hepatitis C Treated with Pegylated Interferon
Alfa-2a (Pegasys) plus Ribavirin
8/12/2008
Eight
Weeks of Pegylated Interferon plus Ribavirin for Genotype
2 Chronic HCV Patients with Rapid Virological
Response (RVR)
8/05/2008
12-
Versus 24-week Treatment with Pegylated Interferon plus
Ribavirin for Genotype 2 or
3 Chronic Hepatitis C Patients
7/11/08
European
Commission Approves Shorter 16-week Course of Pegasys
plus Ribavirin for Rapid Responders with HCV Genotypes
2 or 3 and Low Viral Load
7/04/08
Studies
Explore Lower Doses of Pegylated Interferon and Ribavirin
for People with Hepatitis C Virus Genotypes
2 or 3
7/08/08
Limitations
of an 8-week Course of Pegylated interferon plus Ribavirin
for Genotype 2 Hepatitis
C Patients with Rapid Virological Response
4/24/08
Genetic
Variations in HCV Genotype
3 Core Protein Promote Liver Fat Accumulation
2/26/08
Genotypes
5 and 6 Articles
(Genotype
5 - Africa / Genotype 6 - South East Asia)
Hepatitis C Treatment
Appears to Be Declining; People with Hard-to Treat Genotypes
Are Half as Likely to Receive Therapy
12/01/09
Effectiveness of Pegylated
Interferon plus Ribavirin for Chronic Hepatitis C Patients
with HCV Genotypes 5 or 6
6-19-2009
Effectiveness
of Pegylated Interferon plus Ribavirin for Chronic Hepatitis
C Patients with HCV Genotypes
5 or 6
6/19/2009
Widespread
Hepatitis C Treatment Has Led to a Shift in HCV
Genotypes in Spain
3/27/2009
Individuals
with HCV Genotype 6
Respond Well to Pegylated Interferon plus Ribavirin
10/14/08
|
